Bibliometric analysis reveals that nanotechnology applications in ischemic heart disease primarily focus on therapeutics, tissue engineering, biosensors, and imaging, though clinical translation remains limited.
Bibliometric analysis demonstrates rapid growth in nanomaterial research for ischemic heart disease, primarily focused on preclinical models, targeted drug delivery, and cardiac tissue engineering, though clinical translation remains limited by safety concerns.
Abstract Ischemic heart disease (IHD) remains a leading cause of mortality worldwide. Despite timely reperfusion therapy, myocardial ischemia can still lead to ventricular remodeling, arrhythmia, and heart failure, contributing to the high prevalence of cardiovascular disease. Nanomaterials provides innovative technical methods and tools for precise clinical diagnosis and effective treatment through nanoscale control of materials and biological interactions. In this study, bibliometrics have been harnessed to explore the region and topic distribution characteristics of nanotechnology in the field of ischemic cardiomyopathy. The key directions in this field contain cardiac tissue engineering, biosensor, targeted drug delivery and molecular imaging. China and USA are the leading contributors in this filed. Recent literature demonstrates rapid growth in nanomaterial-based strategies and their broad application in preclinical models of IHD. However, only a limited number of nanomedicine products have progressed to clinical approval. This review summarizes the current advances in nanotechnology for IHD, highlights remaining challenges, and discusses future directions to facilitate clinical translation.
Jiang et al. (Thu,) conducted a review in Ischemic heart disease. Nanotechnology was evaluated. Bibliometric analysis reveals that nanotechnology applications in ischemic heart disease primarily focus on therapeutics, tissue engineering, biosensors, and imaging, though clinical translation remains limited.